Chromium for Blood Sugar
Chromium is the clearest example on this site of an early, striking result that did not survive replication. For two decades it was the standard blood-sugar mineral recommendation. The accumulated evidence has since gone the other way.
Evidence tier 2, and trending down. That direction of travel is the story.
Table of Contents
The Rise and the Fall
In 1997 Anderson and colleagues published a trial in Diabetes reporting that supplemental chromium substantially improved glucose and insulin variables in people with type 2 diabetes, with the striking results at 1,000 µg/day — a dose far above ordinary dietary intake. It was conducted in China, in a population whose baseline chromium status and diet differed from Western trial populations, and it set the expectation for everything that followed.
Nearly twenty years later Costello, Dwyer and Merkel examined the accumulated literature for Nutrition Reviews and reached a blunt conclusion, stated in the title itself: chromium supplements for glycemic control in type 2 diabetes show limited evidence of effectiveness.
This is what a supplement looks like when it does not hold up. Not a scandal, not a retraction — just a promising early finding that later, larger, better-controlled work failed to reproduce. It is the same shape as cinnamon, and it is worth recognising, because the marketing for both still cites the early trials as though nothing happened afterwards.
The Mechanism, and Its Problem
Chromium's proposed role runs through chromodulin (historically "glucose tolerance factor"), an oligopeptide that binds chromium and is said to amplify insulin receptor signalling. The mechanism is plausible and it has a specific weakness: frank chromium deficiency is very rare in people eating ordinary food.
That matters because it makes chromium unlike magnesium, whose disappointing pooled results have a repletion explanation. If almost nobody is deficient, the repletion argument is not available, and supplementation has to work as a pharmacological intervention in replete people — which is exactly what the later evidence suggests it does not do.
Where That Leaves It
Chromium picolinate is inexpensive and, at the doses sold, well tolerated. Nothing here says it is dangerous. What the evidence says is that it is unlikely to do much, and that money and attention spent on it would do more work applied to a tier-1 entry or to the behavioural interventions that cost nothing.
Chromium also appears in combination products with biotin, which is covered on the biotin page.
Cautions
- It lowers blood glucose, and so does your medication. The effects add. With insulin or a sulfonylurea this is a hypoglycemia risk, and dose changes belong with the prescriber — see hypoglycemia awareness and prevention.
- Caution in kidney impairment — there are case reports of renal injury associated with high-dose chromium picolinate.
- Measure, do not assume. Adding a supplement without measuring means you learn about an interaction from a symptom rather than from a number.
Key Research Papers
Every DOI below was checked against Crossref and the abstract read for support before it was listed.
- Anderson RA, Cheng N, Bryden NA, et al. Elevated Intakes of Supplemental Chromium Improve Glucose and Insulin Variables in Individuals With Type 2 Diabetes. Diabetes, 1997;46(11):1786–1791. The trial that started it.
- Costello RB, Dwyer JT, Merkel JM. Chromium supplements for glycemic control in type 2 diabetes: limited evidence of effectiveness. Nutrition Reviews, 2016;74(7):455–468. The review that did not confirm it.